Mapping cellular heterogeneity and dynamic interactions in pancreatic cancer.
TL;DR
A stepwise process workflow that utilizes computational approaches based on experimental requirements is outlined that utilizes signal transducer and activator of transcription 3 blockade and anti-CD47/anti-PD-L1 immunotherapy in preventing PDAC resistance.
OpenAlex 토픽 ·
Single-cell and spatial transcriptomics
Pancreatic and Hepatic Oncology Research
Cancer Cells and Metastasis
A stepwise process workflow that utilizes computational approaches based on experimental requirements is outlined that utilizes signal transducer and activator of transcription 3 blockade and anti-CD4
APA
Tatekalva Sandhya, Seema Kumari, et al. (2026). Mapping cellular heterogeneity and dynamic interactions in pancreatic cancer.. Journal of controlled release : official journal of the Controlled Release Society, 393, 114757. https://doi.org/10.1016/j.jconrel.2026.114757
MLA
Tatekalva Sandhya, et al.. "Mapping cellular heterogeneity and dynamic interactions in pancreatic cancer.." Journal of controlled release : official journal of the Controlled Release Society, vol. 393, 2026, pp. 114757.
PMID
41780688
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is highly aggressive with a high mortality rate. Intra-tumoral heterogeneity (ITH) increases the severity of PDAC and makes treatment difficult. Insights are provided on ITH to understand the diversity of microenvironment (ME) components, biomarkers, different subsets of tumor-associated cells, and immune cells, as well as metabolic reprogramming, autophagy, and apoptosis in PDAC. Single-cell RNA sequencing (scRNA-seq) is a sensitive technique that provides spatially resolved transcriptomic profiling. In this review, we discussed the sample preparation, library preparation, data analysis, and challenges associated with the technology. We have outlined a stepwise process workflow that utilizes computational approaches based on experimental requirements, supported by relevant examples and discussion. We reviewed various studies where scRNA-seq has helped identify dynamic cell subset transformations during tumorigenesis, modulate ME, epithelial-mesenchymal transition, and cancer stem cells enrichment, and identify novel signaling molecules, prognostic gene markers, and therapeutic vulnerabilities for PDAC. Identification of biomarkers such as Matrix metalloproteinase 1 (MMP1) and the S100A2 tumor subset, characterization of the basal-like malignant subtype, and interventions like radiofrequency ablation reshaping the PDAC-ME were also discussed. Additionally, the roles of cancer associated fibroblasts and the therapeutic potential inhibitors in combination with signal transducer and activator of transcription 3 blockade and anti-CD47/anti-PD-L1 immunotherapy were reviewed in preventing PDAC resistance.
MeSH Terms
Humans; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal; Animals; Tumor Microenvironment; Single-Cell Analysis; Biomarkers, Tumor